Avivo Biomedical Inc.

1 known investors

AvivoBio develops enzyme-based technology to convert blood and donor organs into a universal type O, removing ABO blood-type incompatibility as a barrier to transfusions and organ transplants. Its work targets clinicians and the transplant field, aiming to match donations by medical need rather than blood type.